Clinical Research Directory
Browse clinical research sites, groups, and studies.
Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
Sponsor: CHA University
Summary
The goal of this observational study is to evaluate the clinical efficacy and safety of lenvatinib plus pembrolizumab combination therapy in patients with advanced biliary tract cancer (BTC). This study aims to identify potential biomarkers that may predict treatment response by analyzing genetic data from blood and tissue samples. The study will focus on real-world clinical outcomes and the exploratory discovery of biomarkers associated with the efficacy of this treatment regimen.
Official title: Investigation of Predictive Biomarkers in Patients With Advanced Biliary Tract Cancer Treated With Lenvatinib Plus Pembrolizumab
Key Details
Gender
All
Age Range
20 Years - Any
Study Type
OBSERVATIONAL
Enrollment
100
Start Date
2024-09-23
Completion Date
2026-12-31
Last Updated
2026-03-18
Healthy Volunteers
No
Conditions
Interventions
lenvatinib plus pembrolizumab
* The collection of peripheral blood samples will follow the schedule below (20 cc per collection, up to 5 times): * Before systemic therapy, at 3 weeks after starting systemic therapy (Cycle 1), at 6 weeks (Cycle 2) * (If possible) at the time of confirmed partial response (1 time), and at the time of disease progression (1 time). * Additional tumor tissue samples will be collected only if possible, according to the following schedule: If the patient undergoes surgery or additional biopsy related to treatment (collected from preserved specimens).
Locations (1)
Bundang CHA Medical Center
Seongnam-si, Gyeonggi-do, South Korea